Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
JAK Inhibitors in Cutaneous Granulomatous Disease: Mechanisms, Necrobiosis Lipoidica, and Brepocitinib in Cutaneous Sarcoidosis
Description
The talk reviewed the biology and treatment of cutaneous granulomatous diseases, emphasizing shared inflammatory pathways across disorders such as granuloma annulare, necrobiosis lipoidica, necrobiotic xanthogranuloma, and cutaneous sarcoidosis. The speaker explained that environmental triggers and polygenic risk can drive common cytokines and effector cells that lead to granulomas, necrobiosis, scarring, and ulceration, with important roles for interferons, IL-6, TNF-alpha, and related signaling. JAK inhibitors were highlighted as promising targeted therapies, with different agents showing activity across disease subtypes. For necrobiosis lipoidica, topical JAK1/2 inhibition with ruxolitinib produced strong clinical improvement in most patients, and transcriptomic analyses pointed to interferon-gamma and STAT1 as central disease drivers and treatment-response markers. The presentation then focused on brepocitinib, a once-daily oral TYK2/JAK1 inhibitor, in the BEACON phase 2 trial for cutaneous sarcoidosis. In that study, both doses produced rapid, deep, and sustained responses, with the 45 mg group showing especially strong improvements in disease activity, skin scores, patient-reported outcomes, and functional remission, while placebo showed little to no benefit. Overall, the drug was well tolerated with no serious adverse events, and the speaker concluded that JAK-pathway inhibition holds substantial promise for cutaneous granulomatous disease.
View moreConclusions
- Cutaneous granulomatous diseases appear to share a JAK-dependent inflammatory circuit that links environmental or genetic triggers to cytokine-driven tissue damage.
- Among these diseases, necrobiosis lipoidica seems to be strongly interferon-driven, with IFNG and STAT1 emerging as central pathogenic and treatment-response genes.
- Topical JAK1/2 inhibition with ruxolitinib produced meaningful clinical improvement in necrobiosis lipoidica, supporting JAK-STAT blockade as a viable strategy.
- Brepocitinib, a dual TYK2/JAK1 inhibitor, showed rapid, deep, and sustained efficacy in cutaneous sarcoidosis compared with placebo.
- The brepocitinib trial suggested a dose-response relationship, with the 45 mg dose generally producing the strongest clinical and patient-reported benefits.
- Clinical and photographic responses to brepocitinib were fast, often visible by week 4, and continued to improve through week 16.
- Patient-reported outcomes improved alongside physician-assessed disease activity, indicating that the treatment benefit was meaningful to patients as well as clinically measurable.
- Safety findings for brepocitinib were favorable, with no serious adverse events or deaths and only limited treatment-related laboratory abnormalities.
- Overall, JAK-pathway therapies seem promising for both cutaneous and systemic granulomatous disease, but the best agent and target may vary by disease biology.
- Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica#10.1016/j.xjidi.2024.100296
- Wanat, 2015